Skip to main content

Cancer

High Risk Cancer Profiling with Inflammatory Myositis A recent metanalysis of studies suggest you may be able to use certain clinical factors to stratify cancer risk in patients with idiopathic inflammatory myopathies (IIMs). https://t.co/TjmdGtdDQG https://t.co/tlfVU031fY
Dr. John Cush @RheumNow( View Tweet )
Feb 19, 2021

High Risk Cancer Profiling with Inflammatory Myositis

Feb 18, 2021

A recent metanalysis of studies suggest you may be able to use certain clinical factors to stratify cancer risk in patients with idiopathic inflammatory myopathies (IIMs).

Read Article

Checkpoint Inhibitor Use with Pre-existing Autoimmune Disease

Feb 17, 2021

Annals of Internal Medicine reports treating advanced melanoma with immune checkpoint inhibitors (ICI) in patients with pre-existing autoimmune disease (AID) was as effective and safe in those with AID compared to those without AID, although severe colitis occurred more frequently among

Read Article
No increased risk of cancer with TNFi use in PsA patients @RWCSmtg @JointMD https://t.co/7VSI1Fd1hw
Dr. John Cush @RheumNow( View Tweet )
Feb 12, 2021
Danish Cohort study of 5310 cutaneous LE or SLE pts between 1995-2014 (7-8 yrs F/U and 40.724 PYs) shows an overall increased cancer risk for CLE (SIR 1.35)and SLE (1.45), esp a 3-4 fold increased risk for NHL, hematological, pancreatic and lung cancers https://t.co/0FialHXVvb

Dr. John Cush @RheumNow( View Tweet )

Feb 09, 2021
Cardiac and Cancer Signals Tofacitinib Safety Alert from FDA The FDA has notified healthcare professionals of a safety alert concerning tofacitinib when given to at-risk RA patients. https://t.co/RJD8CMouHK https://t.co/j8DMyxsaaf
Dr. John Cush @RheumNow( View Tweet )
Feb 08, 2021
Cardiac and Cancer Signals Tofacitinib Safety Alert from FDA The FDA has notified healthcare professionals of a safety alert concerning tofacitinib (Xeljanz) when given to at-risk rheumatoid arthritis patients. https://t.co/RJD8CMouHK https://t.co/bipwWlIhiB
Dr. John Cush @RheumNow( View Tweet )
Feb 05, 2021

RheumNow Podcast – Tofacitinib Safety Concerns (2.5.2021)

Feb 05, 2021

Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.

Read Article

JAK Inhibitor Misses Endpoint in Safety Study. Now What?

MedPage Today
Jan 27, 2021

Pfizer announced results Wednesday from its FDA-mandated postmarketing safety study of tofacitinib (Xeljanz), and they don't bode well for the drug and possibly others in its class.



Compared with patients taking tumor necrosis factor (TNF) inhibitors, those assigned to tofacitinib (5

Read Article

Lung Cancer Survival With Autoimmune Disease

Dec 15, 2020

Lung cancer risk is often increased with inflammation and autoimmune disease; a recent analysis suggests that patients with autoimmune disease do not have worse survival, even though they may have received less than the standard-of-care treatments.

Read Article
#BestACR20Tweets "RT @drdavidliew : Just a reminder: inflammatory arthritis irAEs can occur at almost any time after immune checkpoint inhibitor cancer immunotherapy is commenced. @LoyolaChicago #ACR20 ABST1566 @RheumNow https://t.co/x7DLzZcn9o https://t.co/OmpTAorA13
Dr. John Cush @RheumNow( View Tweet )
Dec 05, 2020
Dr. Janet Pope ( @Janetbirdope) reviews abstract #1001 presented at #ACR20 on risk of skin cancer with methotrexate. https://t.co/N0JelI6K5p https://t.co/n07HoO5j3y
Dr. John Cush @RheumNow( View Tweet )
Nov 30, 2020
There are a number of important mimics of IgG4-RD that should be considered 🔵ANCA-associated vasculitis 🔵Multicentric Castleman’s disease 🔵Rosai-Dorfman disease 🔵Inflammatory myofibroblastic tumour 🔵Cutaneous plasmacytosis 🔵Erdheim-Chester disease 🔵Malignancy #ACR20

Chris Wincup @chriswincup( View Tweet )

Nov 10, 2020
Just a reminder: inflammatory arthritis irAEs can occur at almost any time after immune checkpoint inhibitor cancer immunotherapy is commenced. @LoyolaChicago #ACR20 ABST1566 @RheumNow https://t.co/qdEpNpzdNs
David Liew @drdavidliew( View Tweet )
Nov 09, 2020
This cohort study presented by @Dr_Alex_Oldroyd shows that early cancer diagnosis after #myositis onset is associated with significantly improved survival. Cancer screening essential in pts newly diagnosed with IIMs. @RheumNow #ACR20 abs1057 https://t.co/qVsnTcEnWb
Nov 08, 2020
Dr Lee reports on risk of melanoma and NMSC risk in RA in cohort study using propensity score matching. No difference in risk between MTX and HCQ overall. Increase BCC in MTX (HR 1.32) but less SCC (HR 0.77) @rheumnow #ACR20 Abstr#1001 https://t.co/LDWgfGK9LS
Richard Conway @RichardPAConway( View Tweet )
Nov 08, 2020
IL-6 blockade for management of irAEs without inhibiting anti cancer immune response. Should these be given prior or concomitantly with ICIs? Some interesting ideas to look up from the cancer and immunotherapy study group. #ACR20 @UTSWNews @ACRheum @RheumNow

Adela Castro @AdelaCastro222( View Tweet )

Nov 06, 2020
Large data from Japanese Ninja database in abst#0183 shows incidence of malignancies in Japanese RA patients similar to Japanese gen pop. Comparable in patients exposed and unexposed to biologics/JAKs. #ACR20 @RheumNow

Eric Dein @ejdein1( View Tweet )

Nov 06, 2020
Lymphomas Complicating Rheumatoid Arthritis: Results of a French Multi-Centre Case-Control Study https://t.co/NDk0LH5Kk6 #RA #lymphoma risk driven by increased disease activity

Peter Nash @drpnash( View Tweet )

Nov 06, 2020
Do you plan to do a skin exam in your RA patients on MTX given new toxicity signal of skin cancer based on CIRT with NNH of 167? @JYazdanyMD #ACR20 Year in Review @RheumNow

Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )

Nov 05, 2020

RheumNow Podcast – ACR 20 is Coming to Town (10.30.20)

Oct 29, 2020

Dr Jack Cush overviews the RheumNow commitment, upcoming bonus coverage of ACR20 and the good news and journal reports from the past week on RheumNow.com

Read Article

ICI Arthritis Tied to Cancer Progression

Oct 14, 2020

Cancer patients treated with immune checkpoint inhibitors (ICI) who develop severe arthritis may be at risk for progression of the malignancy, a single-center study suggested.



Almost 90% of patients treated with ICI develop immune-related adverse events, which can include pulmonary,

Read Article
FDA Issues Final Guidance for Labeling Recommendations on Breast Implants, after review of data & commentary. Implants have been assoc w/anaplastic large cell lymphoma & breast implant illness (BII) w/ fatigue, “brain fog,” rash, myalgia, arthralgia. . https://t.co/HozSCRx4JH

Dr. John Cush @RheumNow( View Tweet )

Oct 02, 2020

In Lupus, Older Age and Male Sex Raise Cancer Risk

Aug 25, 2020

Among patients with systemic lupus erythematosus (SLE), cancer risks overall were associated with older age at diagnosis and male sex, and lung cancer specifically was related to smoking, analysis of data from a large multicenter cohort found.

Read Article
Hong Kong study Myositis-specific autoantibodies in 201 pts with idiopathic inflammatory myopathies (IIM) shows MDA-5 (14%), TIFF-1γ (14%), Jo-(12.4%). MDA5 seen w/ DM, digital ulcers, amyopathy, ILD. TIF1γ was associ w/ refractory rash and cancer https://t.co/3E365F5SON

Dr. John Cush @RheumNow( View Tweet )

Aug 07, 2020
×